The once-weekly dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist tirzepatide outperformed the selective GLP-1 receptor agonist semaglutide in patients with type 2 diabetes who were taking metformin monotherapy, according to the SURPASS trial (196). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.